title: Response to ODN-CpG by B Cells from patients with systemic lupus erythematosus correlates with disease activity.
abstract: Different immunological alterations may condition systemic lupus erythematosus (SLE) activity. However, it is not known whether alterations in the phenotype of circulating antigen-presenting cells (APCs) and in the response to CpG oligodeoxynucleotides (ODN-CpG) correlate with disease activity. APC expression of HLA-DR, costimulatory molecules, and TLR9 expression was determined in patients with SLE, other autoimmune diseases, and healthy controls. Monocyte and B cell response to synthetic ODN-CpG sequences was also evaluated. Monocytes from patients with moderate SLE activity had higher expression of CD40 and CD86. Decreased numbers of CD19+CD80+ and BDCA-3+CD40+ cells were found in patients with severe SLE activity. In patients with moderate SLE activity, non-adherent and enriched B cell response to ODN-CpG was similar to healthy controls. Adherent and enriched B cells from patients with severe SLE activity did not increase costimulatory molecule expression or cytokine production after ODN-CpG stimulation. APCs from patients with SLE, regardless of disease activity, displayed higher percentage of TLR9+ cells, as well as increased expression of TLR9, compared to healthy controls. Results suggest that the B cell response to ODN-CpG correlates with the SLE activity, independently of TLR9 expression, indicating that alterations in B cell response in severe activity SLE may be caused by events down-stream to TLR9.
authors.affiliation: Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia; Department of Immunology, Cancer Center, Scottsdale Mayo Clinic Arizona, Scottsdale, Arizona, USA.
authors.forename: S
authors.initials: S
authors.lastname: Zorro
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: F
authors.initials: F
authors.lastname: Riaño
authors.forename: S
authors.initials: S
authors.lastname: Paris
authors.forename: L A
authors.initials: LA
authors.lastname: Ramírez
authors.forename: O
authors.initials: O
authors.lastname: Uribe
authors.forename: L F
authors.initials: LF
authors.lastname: García
authors.forename: G
authors.initials: G
authors.lastname: Vásquez
mesh_terms: D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D018180:Thrombomodulin; D051217:Toll-Like Receptor 9 / Q000276:immunology; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000954:Antigens, Surface; C408982:CPG-oligonucleotide; D006684:HLA-DR Antigens; D009838:Oligodeoxyribonucleotides; C546931:THBD protein, human; C495371:TLR9 protein, human; D018180:Thrombomodulin; D051217:Toll-Like Receptor 9